Treatment of endogenous depressions with thyrotropin-releasing hormone (TRH) under oral administration.
In a double-blind study among six patients suffering from endogenous depression, three patients received thyrotropin-Releasing Hormone (TRH) administered orally in doses of 20 mg three times a day for 3 weeks. In an open controlled study of three patients suffering from endogenous depression, two patients received oral TRH 20 mg four times a day for 2 weeks. Degree of depression according to Hamilton's Rating Scale measured during the study showed that TRH had no antidepressant effect. Thyroxine concentration in serum (T4) increased during the period of TRH treatment.
D000284:Administration, Oral; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D013974:Thyroxine / Q000097:blood
D013973:Thyrotropin-Releasing Hormone; D007099:Imipramine; D013974:Thyroxine